Cambrex Adds to Large-Scale Manufacturing CapacityBy
Cambrex, a contract manufacturer of small-molecule active pharmaceutical ingredients (APIs), has completed an expansion of large-scale production capacity at its plant in Charles City, Iowa.
The investment included the installation of 1,000- and 4,000-gallon glass-lined reactors in addition to ancillary equipment. The new reactors have been installed in the 7,500-square-foot multi-purpose manufacturing facility that opened at the site in 2016. This brings the cGMP reactor capacity in this newest facility to 23,000 gallons, with the total capacity at the Charles City facility now being approximately 107,000 gallons.
Cambrex’s Charles City facility is located on a 45-acre site and manufactures a range of APIs and pharmaceutical intermediates, including highly potent molecules and controlled substances. The facility is authorized by the US Drug Enforcement Administration to import narcotic raw materials at commercial-scale.
This latest expansion follows the announcement of the construction of a $24-million, 4,500-square-foot highly potent API manufacturing facility at the Charles City facility, which is due to open in 2019.